Introduction to 21 CFR 201.128
The 21 CFR 201.128 regulation outlines the requirements for the Principal Display Panel of pharmaceutical products and medical devices. This regulation is enforced by the FDA to ensure that labeling is accurate, clear, and consistent.
The Principal Display Panel is the primary display panel of a product, and it must contain specific information, such as the product's name, dosage, and warnings. Compliance with 21 CFR 201.128 is crucial to avoid FDA enforcement actions and ensure public safety.
Key Requirements of 21 CFR 201.128
The regulation specifies that the Principal Display Panel must contain the product's established name, dosage, and route of administration. It must also include any relevant warnings, cautions, or contraindications.
Additionally, the labeling must be presented in a clear and concise manner, using a font size and style that is easily readable. The FDA also requires that the labeling be reviewed and updated periodically to reflect any changes in the product's safety or efficacy.
Consequences of Non-Compliance
Failure to comply with 21 CFR 201.128 can result in significant consequences, including FDA warning letters, product recalls, and civil penalties. Non-compliance can also damage a company's reputation and lead to financial losses.
To avoid these consequences, companies must ensure that their labeling complies with all applicable regulations, including 21 CFR 201.128. This requires a thorough understanding of the regulation and its requirements, as well as a robust quality control process to ensure compliance.
Best Practices for Compliance
To ensure compliance with 21 CFR 201.128, companies should establish a comprehensive labeling review process that includes a thorough review of the Principal Display Panel. This process should involve multiple stakeholders, including regulatory affairs, quality assurance, and marketing.
Companies should also stay up-to-date with any changes to the regulation and ensure that their labeling is updated accordingly. This may involve conducting regular audits and assessments to identify any potential compliance issues.
Conclusion
In conclusion, 21 CFR 201.128 is a critical regulation that requires pharmaceutical and medical device companies to ensure that their labeling is accurate, clear, and consistent. Compliance with this regulation is essential to avoid FDA enforcement actions and ensure public safety.
By understanding the requirements of 21 CFR 201.128 and implementing best practices for compliance, companies can minimize the risk of non-compliance and ensure that their products are safe and effective for consumers.
Frequently Asked Questions
What is the purpose of 21 CFR 201.128?
The purpose of 21 CFR 201.128 is to ensure that pharmaceutical and medical device labeling is accurate, clear, and consistent.
What information must be included on the Principal Display Panel?
The Principal Display Panel must include the product's established name, dosage, and route of administration, as well as any relevant warnings or cautions.
What are the consequences of non-compliance with 21 CFR 201.128?
Non-compliance can result in FDA warning letters, product recalls, and civil penalties, as well as damage to a company's reputation and financial losses.
How often must labeling be reviewed and updated?
Labeling must be reviewed and updated periodically to reflect any changes in the product's safety or efficacy.
What is the role of quality control in ensuring compliance with 21 CFR 201.128?
Quality control plays a critical role in ensuring compliance by reviewing and verifying the accuracy and completeness of labeling.
Where can I find more information about 21 CFR 201.128?
More information about 21 CFR 201.128 can be found on the FDA website or by consulting with a regulatory expert.